Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|November 1, 2019

BioPharm International

  • BioPharm International-11-01-2019
  • Volume 32
  • Issue 11

KUBio Box for Viral Vectors

GE Healthcare Life Sciences launched the new KUBio box for the production of viral vector-based gene therapies.

GE Healthcare Life Sciences launched the new KUBio box for the production of viral vector-based gene therapies. The device is the most recent addition the company’s KUBio modular bioprocessing portfolio.

Designed to fit into new facilities and retrofitted existing spaces, the new device supports up to 200-L scale manufacturing, comes equipped with a biosafety level 2 (BSL-2) modular bioprocessing environment, and features a FlexFactory single-use biomanufacturing platform specifically for the production of viral vectors.

The design also supports future expansion at different production scales and product technologies.

GE Healthcare Life Sciences
 

 

 


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.